• Traitements

  • Combinaison de traitements localisés et systémiques

  • Sarcome

Quality of surgery and neoadjuvant combined therapy in the ISG-GEIS trial on soft tissue sarcomas of limbs and trunk wall

Mené sur 252 patients ayant subi une chirurgie conservatrice pour traiter un sarcome des tissus mous des membres et de la paroi du tronc à haut risque (durée médiane de suivi : 60 mois), cet essai randomisé de phase III évalue, du point de vue de la survie globale à 5 ans et de la récidive locale, l'association entre la qualité des marges de résection et l'efficacité d'une chimiothérapie et d'une radiothérapie néoadjuvantes, seules ou en combinaison

Background To explore correlation between the quality of surgery and outcome in high-risk soft tissue sarcoma (STS) patients treated within a phase III randomized trial. Patients and Methods In the trial, all patients received three cycles of preoperative chemotherapy (CT) with epirubicin 120 mg/m2 and ifosfamide 9 g/m2 and were randomly assigned to receive two further postoperative cycles. Radiotherapy (RT) could be delivered in the preoperative or postoperative setting. The association between surgical margins and overall survival (OS) was studied in a univariate and multivariate fashion. Results Two hundred and fifty-two patients completed the whole treatment and were operated conservatively. At a median follow-up of 60 months (IQR, 45–74 months), the 5-year OS was 0.73, even in patients with positive and negative margins. The 5-year cumulative incidence (CI) of local recurrence (LR) in patients with positive and negative microscopic margins was 0.17 (standard error, SE, 0.08) and 0.03 (SE, 0.01), respectively. In the subgroup of patients receiving combined preoperative CT–RT and with positive surgical margins, the CI of LR was 0.Conclusions In this setting of high-risk STS treated by preoperative CT or CT–RT, the negative impact of positive margins on the outcome was limited. When close margins can be anticipated preoperative CT–RT may be a reasonable option to maximize the chance of cure.

Annals of Oncology

Voir le bulletin